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ABSTRACT
We describe previously transfused patients with sickle cell disease (n  6) and thalassemia (n  1) who received
nonmyeloablative hematopoietic stem cell transplantation (HCT) to induce stable (full or partial) donor engraft-
ment. Patients were 3 to 20 years (median, 9 years) old. All 7 received pretransplantation fludarabine and 200 cGy
of total body irradiation; 2 patients also received horse antithymocyte globulin. Patients received bone marrow (n
6) or peripheral blood stem cells (n 1) from HLA-identical siblings, followed by a combination of mycophenolate
mofetil and cyclosporine or tacrolimus for postgrafting immunosuppression. After nonmyeloablative HCT, abso-
lute neutrophil counts were <0.5  109/L and <0.2  109/L for a median of 5 days (range, 0-13 days) and 0 days
(range 0-13 days), respectively. A median of 0 (range, 0-9) platelet transfusions were administered. No grade IV
nonhematologic toxicities were observed. One patient experienced grade II acute graft-versus-host disease. Two
months after transplantation, 6 of 7 patients had evidence of donor chimerism (range, 25%-85%). Independent of
red blood cell transfusions, these 6 patients initially had increased total hemoglobin and hemoglobin A concentra-
tions and a reduction of reticulocytosis and transfusion requirements. There were no complications attributable to
sickle cell disease during the interval of transient mixed chimerism. However, after posttransplantation immuno-
suppression was tapered, there was loss of the donor graft, and all patients experienced autologous hematopoietic
recovery and disease recurrence. One patient did not engraft. The duration of transient mixed chimerism ranged
from 97 to 441 days after transplantation in patients 4 and 6, respectively, and persisted until immunosuppressive
drugs were discontinued after transplantation. In summary, the nonmyeloablative HCT regimens described here
produced minimal toxicity and resulted in transient donor engraftment in 6 of 7 patients with hemoglobinopathies.
Although complications from the underlying hemoglobinopathies did not occur during the period of mixed
chimerism, these results suggest that stable (full or partial) donor engraftment after nonmyeloablative HCT is more
difficult to achieve among immunocompetent pediatric patients with hemoglobinopathies than among adults with
hematologic malignancies, perhaps in part because recipients may have been sensitized to minor histocompatibility
antigens of their donor by preceding blood transfusions.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Despite advances in supportive treatment and pre-
ventive measures, sickle cell disease (SCD) remains a
chronic disease with attendant risks of signiﬁcant mor-
bidity and early mortality. As a result, there has been
considerable interest in deﬁning the role of hemato-
poietic stem cell transplantation (HCT) for SCD as a
curative alternative to therapies such as supportive
care, regular red blood cell (RBC) transfusions, and
hydroxyurea. The potential for a successful outcome
after transplantation was illustrated in a recent review
that described 175 patients with SCD who received
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myeloablative HCT from HLA-identical sibling do-
nors. One hundred ﬁfty-nine (91%) patients survived,
and 143 (82%) survived free of SCD [1]. However,
efforts to expand the application of HCT for SCD
have been tempered in part by the risk of signiﬁcant
toxicity that accompanies this intensive procedure.
Among the 175 patients treated by HCT, graft rejec-
tion and recurrent disease was observed in 16 (9%)
and 17 (9%) patients who died of transplant-related
causes. In a prospective series of 59 patients, 4 patients
died from transplant-related causes that included in-
tracranial hemorrhage (n  1) and graft-versus-host
disease (GVHD; n  3) [2]. There were other revers-
ible acute toxicities, such as seizures and other neuro-
logic complications, in 13 patients. Long-term com-
plications included infertility and gonadal failure,
particularly among females, and a potential for sec-
ondary malignancies. Although these initial transplan-
tation studies show that most very high-risk patients
with SCD would beneﬁt from this therapy, concerns
about mortality and long-term effects have generated
attitudes among families and clinicians that justiﬁably
curb their willingness to consider transplantation
more broadly [3-5]. Thus, currently this therapy is
generally reserved for those who have experienced
signiﬁcant complications of SCD. To consider trans-
plantation for SCD before irreversible vital organ
damage has occurred and thereby expand its availabil-
ity, it is likely that improvement in the risk-beneﬁt
ratio must ﬁrst be achieved.
Nonmyeloablative HCT may represent an effec-
tive strategy to reduce the toxicity of transplantation,
as was shown in canine transplantation models [6] and
in older debilitated patients with hematologic malig-
nancies [7-10]. There is considerable evidence from
preclinical models [11,12] and from clinical transplan-
tation trials that mixed hematopoietic chimerism, a
possible outcome of nonmyeloablative HCT, is asso-
ciated with clinical beneﬁt for SCD [13] and thalasse-
mia [14]. These observations have supported the
development of pilot clinical trials to evaluate nonmy-
eloablative HCT for these disorders. Here we illus-
trate the challenge of establishing full or partial donor
chimerism that is stable in immunocompetent patients
with hematological disorders by describing a series of
7 patients with SCD and -thalassemia major who
underwent HLA-identical sibling HCT after nonmy-
eloablative conditioning.
METHODS
Patients
Between December 1999 and November 2001, 6
patients with SCD and 1 with -thalassemia major
received nonmyeloablative HCT from HLA-matched
sibling donors at the Johns Hopkins Hospital, Stan-
ford University Medical Center, Children’s Hospital
and Research Center at Oakland, and the Fred
Hutchinson Cancer Research Center. This case series
describes all patients who were treated according to
different institutional review board–approved clinical
protocols that used similar pretransplantation condi-
tioning and posttransplantation immunosuppression.
There were 3 independent clinical trials conducted at
Fred Hutchinson Cancer Research Center/Oakland,
Stanford, and Johns Hopkins.
Treatment Regimen
After written, informed consent was obtained, all 7
patients were enrolled in prospective clinical investi-
gations that were reviewed and approved by each
center’s institutional review board. Patients were in-
formed about conventional myeloablative HCT as an
alternative therapy and either were ineligible or chose
instead to participate in an institutional review board–
approved clinical trial of nonmyeloablative HCT.
Pretransplantation conditioning regimens are
summarized in Table 1. Patients 1, 2, and 3 were
treated at Johns Hopkins Hospital, and all 3 patients
received gonadal and head shielding during total body
irradiation. Patients 4 and 5 were treated at Stanford
University Medical Center and also received horse
antithymocyte globulin 10 mg/kg/d on each of 4
consecutive days, commencing 4 days before nonmy-
eloablative HCT. Patients 4 and 5 received granulo-
cyte-macrophage colony-stimulating factor after non-
myeloablative HCT. Patient 5 received an infusion of
umbilical cord blood from the same donor approxi-
mately 8 months after the initial transplantation, with-
out any preinfusion preparation, in an unsuccessful
attempt to rescue donor hematopoiesis. Patient 6 was
treated at the Children’s Hospital and Research Cen-
ter at Oakland, and patient 7 was treated at the Fred
Hutchinson Cancer Research Center. Both received 3
days of ﬂudarabine.
Six of the 7 patients received HLA-identical sib-
ling bone marrow, and patient 4 received HLA-iden-
tical, mobilized peripheral blood stem cells (PBSC).
Other donor characteristics are summarized in Ta-
ble 1.
For postgrafting immunosuppression, patients 1,
2, and 3 received a combination of tacrolimus (FK-
506) and mycophenolate mofetil (MMF). FK-506 dos-
ing commenced 1 day before nonmyeloablative HCT
and was administered until approximately 200 days
after nonmyeloablative HCT, when it was tapered and
discontinued over 30 days. MMF dosing was com-
menced on the day of transplantation and was admin-
istered until 2 weeks after FK-506 was discontinued,
when it was tapered and discontinued over 30 days.
Patients 4 and 5 received cyclosporine (CsA), which
was commenced 1 day before nonmyeloablative HCT,
R. Iannone et al.
520
Table 1. Patient and Donor Characteristics and Transplantation Procedure
Patient
No.*
Age
(y)/Sex Disease
Major Complications
before Transplantation
RBC
txn
Treatment
Regimen†
Stem Cell
Source
Donor Graft Composition
Host/
Donor
ABO
Hb
Type Sex
TNC per
kilogram
(108)
CD34 per
kilogram
(106)
CD3 per
kilogram
(107)
1 7/M Hb SDLA Infarct on MRI,
neurocognitive changes
2.5 y Flu  5, 200 cGy, FK-506/
MMF
Unprocessed BM Compatible AS F 5.5 11.3 3.9
2 9/M Hb SS Right middle and anterior
cerebral artery strokes
while on transfusion for
TIA
5 y Flu  5, 200 cGy, FK-506/
MMF
Unprocessed BM Compatible AA M 5.1 9.6 5.3
3 20/F Hb SS Frequent VOE, ataxia, and
dysarthria from idiopathic
cerebritis
1 y‡ Flu  5, 200 cGy, FK-506/
MMF
Plasma-depleted BM A/O AS F 1.21 1.11 4.1
4 11/F 0 Cholelithiasis 11 y Flu  5, 200 cGy,
CsA/MMF, ATG
PBSC Compatible AA M 17 9.7 31
5 3/M Hb SS ACS  1, splenic
sequestration,
splenectomy
16 u Flu  5, 200 cGy,
CsA/MMF, ATG
Unprocessed BM Compatible AS F 5.8 8.3 3
6 5/F Hb SS Hospitalization for VOE  2 <5 u Flu  3, 200 cGy, CsA/MMF Unprocessed BM Compatible AA M 4.6 N/A N/A
7 12/M Hb SS Frequent VOE, ACS  1,
aplastic crisis, seizures,
ischemic changes on MRI,
NI MRA, NI TCD
6 u Flu  3, 200 cGy, CsA/MMF RBC-depleted BM O/A AS F 1.5 4.8 9.2
° indicates  thalassemia major; MRI, magnetic resonance imaging; TIA, transient ischemic attack; VOE, painful vaso-occlusive episode; ACS, acute chest syndrome; NI, normal; MRA, magnetic
resonance arteriography; TCD, transcranial Doppler; RBC, red blood cell transfusions; Flu, ﬂudarabine; FK-506, tacrolimus; MMF, mycophenolate mofetil; CsA, cyclosporine; BM, bone marrow; TNC,
total nucleated cells; N/A, not available; txn, transfusion exposures/duration; y, years; u, units.
*Patients 1, 2, and 3 were treated at Johns Hopkins, patients 4 and 5 at Stanford, patient 6 at Oakland, and patient 7 at the Fred Hutchison Cancer Research Center.
†Fludarabine dose: 30 mg/m2/d; ATG dose, 10 mg/kg/d  4 days.
‡Patient 3 also received hydroxyurea for 1 year.
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was administered until 60 days after nonmyeloablative
HCT, and was tapered thereafter. MMF was admin-
istered for 30 days after nonmyeloablative HCT,
when it was discontinued without a taper. Patients 6
and 7 received CsA for 120 days and MMF for 35 days
after nonmyeloablative HCT, respectively. In general,
CsA and FK-506 were administered intravenously and
converted to oral administration after therapeutic
blood concentrations were achieved. Levels were
monitored on a weekly basis to maintain CsA levels
between 150 and 300 ng/mL and FK-506 levels be-
tween 5 and 15 ng/mL. Once a steady-state plasma
level was established, therapeutic monitoring was per-
formed at the discretion of the attending physician.
MMF was administered orally without therapeutic
monitoring.
Before nonmyeloablative HCT, all SCD patients
received RBC transfusions to achieve a fraction of
hemoglobin (Hb) S 30% in the blood. Thereafter,
RBC transfusions were administered by the treating
physicians in consultation with the patient’s hematol-
ogist on an individual basis. All patients who were
seronegative for cytomegalovirus received cytomega-
lovirus antibody–screened negative or leukocyte-poor
blood products. Patients also received prophylactic
antibiotics after transplantation, according to institu-
tional standards. To prevent neurologic complications
after transplantation, the following guidelines were
used: anticonvulsant prophylaxis was initiated with
CsA/FK-506 dosing and continued for 6 months after
transplantation (or until CsA was discontinued); strict
control of hypertension; prompt repletion of magne-
sium deﬁciency; and maintenance of platelet counts
50  109/L.
Donor Chimerism Analysis
Chimerism in the bone marrow was measured by
ﬂuorescence in situ hybridization with an X and Y
chromosome–speciﬁc enumerator probe [15] in pa-
tients 1 and 7 and by restriction fragment length
polymorphism [16] analysis in patients 2 and 3, ac-
cording to previously published methods. Patients 1,
2, and 3 also had chimerism in the blood measured by
polymerase chain reaction–based analysis of germline
microsatellite short tandem repeats (STRs), exploiting
DNA differences between the recipient and donor
(ABI Proﬁler; Applied Biosystems, Foster City, CA).
Patients 4 and 5 had chimerism measured by using
minisatellite variable number tandem repeat genetic
markers to distinguish donor and host cells. Donor
chimerism was measured in patient 6 with informative
STR markers or amelogenin (X and Y) markers am-
pliﬁed by polymerase chain reaction by using the Ge-
neprint Fluorescent STR Quadriplex assay (Promega,
Inc., Madison, WI). Patients 4 through 7 also had
donor chimerism measured in speciﬁc lineages after
cell sorting [16], according to previously described
methods.
Assessments of Disease Status
All patients were monitored regularly with com-
plete blood counts, absolute neutrophil counts (ANC),
reticulocyte counts, and quantiﬁcation of Hb types by
high-performance liquid chromatography. The at-
tending physicians also carefully monitored and
treated patients for manifestations of SCD or thalas-
semia, as dictated by good clinical practice.
Statistical Analysis
Correlation coefﬁcients between paired bone mar-
row and peripheral blood chimerism assessments were
derived from calculations of Pearson product mo-
ments by using SigmaPlot statistical software (SPSS
Inc., Chicago, IL).
RESULTS
Patient Characteristics
Seven patients with SCD (n  6) or -thalassemia
major (n  1) from 4 transplantation centers under-
went nonmyeloablative HCT with bone marrow (n 
6) or PBSC (n  1) from HLA-identical sibling do-
nors. Patients ranged in age from 3 to 20 years (me-
dian, 9 years; mean, 9.6 years). Prior complications in
patients with SCD included cerebral infarction in 3
patients, frequent painful episodes in 2 patients, and
acute chest syndrome in 1. Four patients received
regular RBC transfusions with a duration ranging
from 1 to 10 years before nonmyeloablative HCT, 1
patient had 16 RBC transfusions, and 2 patients had 6
or fewer pre–nonmyeloablative HCT transfusion ex-
posures. There was 1 major (patient O, donor A)
and 1 minor (patient A, donor O) ABO antigen
incompatibility among the 7 donor-host pairs. Four of
7 sibling donors had sickle cell trait. Table 1 summa-
rizes patient and donor characteristics.
Complications after Nonmyeloablative HCT
Nonmyeloablative pretransplantation condition-
ing and posttransplantation immunosuppression were
associated with only low-grade toxicity, and all 7 pa-
tients were alive a median of 28 months (range, 16-40
months) after nonmyeloablative HCT. Patients ini-
tially were hospitalized during the procedure for a
median of 16 days (range, 0-52 days; mean, 15.7 days),
and 2 patients never required hospitalization. Four of
7 patients required subsequent hospitalizations. The
median number of total hospital days was also 16
(range, 0-81; mean, 24.6). There were no life-threat-
ening infections. Two patients had transient grade III
mental status changes. Patient 3 had visual and audi-
R. Iannone et al.
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tory hallucinations while receiving opioid analgesics,
phenytoin, and FK-506. FK-506 levels were in the
therapeutic range, but phenytoin was increased. These
symptoms resolved after the phenytoin dosing was
reduced. Patient 7 developed ataxia and dysarthria
when plasma phenytoin levels were supratherapeutic;
these symptoms also resolved after phenytoin was dis-
continued. Neither patient had evidence of new ab-
normalities by neurologic examination or by magnetic
resonance imaging.
Patient 7 developed grade II acute GVHD after
nonmyeloablative HCT. He had a complete response
after corticosteroid treatment. There was no evidence
of chronic GVHD in any of the 7 patients.
Hematologic Recovery
Donor graft composition for all patients is detailed
in Table 1. Notably, patient 3 received a decreased
CD34 dose; however, there were no apparent donor
clinical characteristics to account for the poor yield.
The tempo of hematologic recovery after nonmyeloa-
blative HCT is depicted in Figure 1. Among all 7
patients, the median number of days that the ANC
remained 0.5  109/L was 5 (range, 0-13 days;
mean, 4.4 days), and for a level of 0.2  109/L, the
median time was 0 days (range, 0-13 days; mean, 1.9
days). As depicted in Figure 1A, patients 1, 2 and 5
experienced a nadir in ANC between 10 and 14 days
after transplantation. Patient 6 had a nadir in ANC
later, at approximately 3 weeks, and patients 3 and 7
had a nadir at approximately 4 to 5 weeks. Patient 3,
who received a total nucleated donor cell dose of
1.21  108/kg, did not recover with donor cells after
nonmyeloablative HCT and thus experienced a pro-
longed period of neutropenia that accompanied autol-
ogous recovery.
In general, thrombocytopenia after nonmyeloab-
lative HCT was mild and had a short duration. Four of
7 patients had platelet measurements that were never
50  109/L (Figure 1B). Most patients had full
recovery by 4 to 7 weeks after nonmyeloablative
HCT. Patient 3, who received a low donor cell dose,
had prolonged neutropenia and thrombocytopenia
that required platelet transfusion support between 20
and 40 days after nonmyeloablative HCT. However,
among all 7 patients, the median number of platelet
transfusions administered was 0 (range, 0-9; mean,
1.6). The number of platelet and red cell transfusions
given after transplantation for each patient, and other
observations made after transplantation, are detailed
in Table 2.
Engraftment and Mixed Chimerism after
Nonmyeloablative HCT
The fraction of donor cells in mononuclear cell
populations in the blood and marrow for patients who
had engraftment of donor cells ranged from 25% to
85% approximately 2 months after nonmyeloablative
HCT (Figure 2A). Three of 4 patients who had CD3
T-lymphocyte donor chimerism measured 28 days
after nonmyeloablative HCT showed levels that were
10%, whereas a higher fraction of 45% was ob-
served in patient 4, who received PBSC in lieu of bone
marrow (Figure 2B). However, by 100 days after non-
myeloablative HCT, the fraction of donor T lympho-
cytes in the blood decreased to20% in all 4 patients.
Engraftment of donor cells resulting in donor-
host mixed hematopoietic chimerism was detected by
day 30 in 6 of 7 patients (Figure 2A). Mixed chimerism
was associated with a reduction in the Hb S and Hb D
fractions and the reticulocyte count and, in some,
increased Hb concentrations. The effect of donor en-
graftment on hematologic parameters was most pro-
nounced in patients 1, 2, and 6, one of whom had
donor engraftment that persisted for up to 14 months
Figure 1. Hematologic recovery after nonmyeloablative hemato-
poietic stem cell transplantation (HCT). A, Neutrophil levels after
nonmyeloablative HCT are depicted. The duration of having an
ANC0.5 109/L was5 days for most patients. In patient 3, the
ANC decreased to 0 after a low dose of CD34 cells in the marrow
inoculum; donor engraftment was never shown. B, Serial platelet
count determinations after nonmyeloablative HCT are depicted.
After nonmyeloablative HCT, the platelet count was never 50 
109/L in 4 of 7 patients. Patient 3 experienced profound thrombo-
cytopenia and received multiple platelet transfusions from 20 to 40
days after nonmyeloablative HCT.
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after nonmyeloablative HCT. In these patients, a
small fraction of donor cells in the marrow was sufﬁ-
cient for a clinically signiﬁcant decrease in the pa-
tients’ endogenous Hb fraction, a reduction in reticu-
locytosis, and a modest increase in the Hb
concentration (Figure 3). During the period when
patient 1 had 30% to 50% donor chimerism in mar-
row, the endogenous Hb fraction (Hb DLA) was less
than 3%, indicating 6% host RBC in the blood.
Patient 2 had an endogenous Hb fraction (Hb S) that
was13%, with 25% donor chimerism, and patient 6,
who had peripheral blood donor chimerism of 4% to
7% that persisted for 1 year after nonmyeloablative
HCT, had an endogenous Hb fraction (Hb S) that
varied from 20% to 50%. Patient 4, who had thalas-
semia major and received a single RBC transfusion in
the ﬁrst week after nonmyeloablative HCT, main-
tained an Hb concentration that ranged from 9 to 10.6
g/dL during the 3 months after nonmyeloablative
HCT when donor chimerism was detectable. Of in-
terest, although Hb concentrations increased and the
fraction of abnormal Hb was low, most patients had
mild to moderate anemia with relatively low reticulo-
cyte counts during CsA and MMF administration.
During the period of mixed donor-host hematopoi-
etic chimerism, none of the 5 SCD patients who had
evidence of donor engraftment experienced sickle-re-
lated clinical events, such as pain, acute chest syndrome,
or stroke. After posttransplantation immunosuppression
was withdrawn, each of these 6 patients experienced
nonfatal graft rejection. The duration of transient mixed
chimerism ranged from 97 to 441 days after transplan-
tation in patients 4 and 6, respectively. A decline in
donor chimerism was temporally associated with discon-
tinuation of immunosuppression in all patients, corre-
sponding to approximately day 220 in patients 1 and 2,
day 60 in patients 4 and 5, and day 120 in patients 6 and
7 (Figures 2A, 3A, and 3B). The level of donor chimer-
ism in patient 6 stabilized after treatment withMMFwas
reinstituted on day 161 but declined after the dose of
MMFwas decreased again on day 182 (Figure 3C). After
the loss of donor hematopoiesis, all patients reverted to
their pre–nonmyeloablative HCT hemoglobinopathy
condition with autologous hematopoiesis.
Patient 4 subsequently received a second HCT
from the same sibling donor after myeloablative
conditioning with total body irradiation (12 Gy),
cyclophosphamide (120 mg/kg), and antithymocyte
globulin. Twenty-two months after myeloablative
transplantation, she has stable full donor chimerism.
Patient 7 had a major ABO incompatibility with
signiﬁcant isohemagglutinin titers before nonmyeloa-
blative HCT (anti-A immunoglobulin M, 1:2035; im-
munoglobulin G, 1:512). Although the anti-A titers
declined after nonmyeloablative HCT, there was no
evidence of circulating donor RBC until anti-A titers
became undetectable. Six months after nonmyeloab-
lative HCT, this patient developed an acute exacerba-
tion of anemia with circulating anti-c, anti-E, anti-
FyA, and anti-JkB antibodies that coincided with loss
of the donor graft. Increasing anti-A titers were noted,
and the anti-c antibody was donor speciﬁc.
DISCUSSION
This report describes our initial experience of al-
logeneic transplantation for SCD and thalassemia ma-
jor after preparation with minimally toxic regimens,
administered with the aim of reducing the toxicity of
allogeneic transplantation while retaining its efﬁcacy
by achieving full or partial donor engraftment. The
rationale for pursuing this approach in light of the
very good results of conventional allogeneic trans-
plantation for sickle cell anemia has to do with (1)
concerns among families and their physicians about
the risks of transplantation and how these signiﬁcantly
limit the application of this curative therapy and (2)
the observation that patients who develop full or par-
tial donor chimerism are protected from the clinical
complications of SCD [11-14]. Were a less-toxic
transplantation regimen successful, HCT could more
readily be used before the onset of irreversible com-
plications rather than to prevent additional complica-
Table 2. Posttransplantation Outcomes
Patient
No.
Initial
Hospital
Days
Total
Hospital
Days
Days with ANC
<0.5  109/L
Days with ANC
<0.2  109/L
Platelet
Transfusions*
Red Blood Cell
Transfusions during Study
MMF/CsA†
Stop Day
1 10 10 5 0 0 None after day 18 224/209
2 16 16 8 0 0 None after day 25 217/197
3 52 81 13 13 9 6 110/110
4 0 6 0 0 0 None after day 7 31/67
5 0 1 0 0 0 Days 10 and 217 28/60
6 7 16 0 0 1 Days 10, 21, 38, and 98 34/120
7 25 42 5 0 1 6; 4 before day 150, became
alloimmunized
35/120
*Platelet transfusions were given to maintain counts 50  109/L.
†Some patients received tacrolimus rather than CsA (see Methods).
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tions in already severely affected patients. The prelim-
inary experience presented here conﬁrmed that,
transiently, even partial donor engraftment was sufﬁ-
cient in most patients to suppress clinical expression of
the underlying hemoglobinopathy. In addition, the
degree of neutropenia and thrombocytopenia was
modest and tended to conﬁrm a reduction in toxicity
and other life-threatening complications after nonmy-
eloablative HCT compared with conventional my-
eloablative allografting. Unfortunately, donor en-
graftment was not sustained in any of the 7 patients,
and all had full autologous hematopoietic recovery
after the tapering of postgrafting immunosuppression.
These observations seem to underscore the prob-
lem of graft rejection and disease recurrence that oc-
curred in approximately 10% of patients after conven-
tional myeloablative transplantation for SCD and
thalassemia, a 5- to 10-fold increased incidence com-
pared with that in patients who undergo myeloablative
transplantation for hematologic malignancies. The in-
crease may be due in part to sensitization to minor
histocompatibility antigens from prior blood transfu-
sions. Our results also contrast sharply with similarly
minimally toxic regimens in adults with hematologic
malignancies, 80% of whom had stable donor engraft-
ment [10]. Thus, there are important differences be-
tween pediatric patients with hemoglobinopathies and
adults with hematologic malignancies which hinder
current efforts to induce donor-speciﬁc tolerance.
Like those with chronic myelogenous leukemia and
myelodysplastic syndrome, patients with hemoglobi-
nopathies are unlikely to have been immunosup-
pressed by exposure to intensive chemotherapy before
nonmyeloablative HCT, possibly predisposing them
to a higher rate of graft rejection [10]. Unfortunately,
whereas augmenting the pretransplantation regimen
by the addition of ﬂudarabine produced stable en-
graftment among 28 consecutive chronic myeloge-
nous leukemia patients [17], it did not produce stable
engraftment in our patients with SCD and -thalas-
semia major.
It is possible that donor T-cell engraftment and
the accompanying allogeneic effect was not sufﬁcient
in these patients to establish stable donor chimerism.
Of interest, none of the 4 patients evaluated in our
series had donor T-cell chimerism that exceeded 50%
after transplantation, and only 1 patient developed
GVHD, which was grade II. In addition, the median
donor marrow chimerism sampled at 56 days after
transplantation was 45% (range, 0%-85%), compared
with 95% (range, 2%-100%) among adults with he-
matologic malignancies [10]. This suggests that the
level of host myelosuppression and immunosuppres-
sion was generally lower in our series compared with
patients who received intensive chemotherapy treat-
ment for hematologic malignancies before nonmy-
eloablative HCT. It is not known to what extent
inherent immunologic differences between children
and adults could explain the greater barrier to achiev-
ing stable donor engraftment in our series. Patient 6
illustrates that prolonging posttransplantation im-
mune suppression is not likely to result in stable donor
chimerism. In this patient, reinstitution of MMF re-
versed the trend toward waning donor chimerism, but
only while MMF therapy was continued. The use of
higher doses of hematopoietic stem cells by the mo-
bilization of allogeneic peripheral blood mononuclear
Figure 2. Engraftment of donor cells after transplantation. A, The
percentages of donor engraftment measured in unfractionated
blood and bone marrow mononuclear cell preparations are plotted
as a function of time in days after transplantation. Chimerism
fraction results from blood and bone marrow samples were closely
correlated (r  0.85). In cases in which blood and marrow mea-
surements were performed on the same day, results from marrow
are shown. There was a decrease in donor chimerism 200 days after
nonmyeloablative HCT in patients 1 and 2, 60 days after nonmy-
eloablative HCT in patients 4 and 5, and 120 days after nonmy-
eloablative HCT in patients 6 and 7. B, The level of donor T-cell
chimerism (CD3 cells) in peripheral blood after nonmyeloablative
HCT for patients 4 through 7 is depicted. These low levels contrast
with a higher level of donor chimerism among unfractionated
mononuclear cells (patients 5 through 7; panel A).
Nonmyeloablative BMT for SCD
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cells in lieu of bone marrow is a strategy that might be
used to promote donor engraftment; however, this
was not sufﬁcient in patient 4.
Driven by a desire to mitigate the risk of rejection,
several recent reports of stable engraftment after
transplantation for SCD used intermediate-intensity
regimens that relied on immunosuppression and my-
elosuppression to prevent a host-versus-graft reaction
and promote engraftment [18-20]. However, also in
contrast to the minimally toxic regimens described
here, the intermediate-intensity regimens were asso-
ciated with prolonged hospitalization and were ac-
companied by an increased risk of regimen-related
toxicity. Patients who received intermediate-intensity
regimens beneﬁted from augmented pregrafting im-
munosuppression that facilitated engraftment of do-
nor cells, but severe acute and chronic GVHD oc-
curred that was fatal in some, particularly among those
who received PBSC allografts and developed full do-
nor chimerism [20]. Thus, the problem of transplant-
related mortality was not eliminated by the interme-
diate-intensity regimens, especially among older
recipients.
In summary, the barrier to stable full or partial
donor engraftment after nonmyeloablative HCT in
pediatric patients with hemoglobinopathies seems
more difﬁcult to overcome than in adults with hema-
tologic malignancies. The minimal toxicity observed
in this case series and the lack of symptoms attribut-
able to SCD that accompanied transient low-level
donor chimerism provide a rationale to pursue this
approach of reducing the toxicity of transplantation
and thus make it more widely available to patients
with hemoglobinopathies. Follow-up studies are un-
der way to determine whether it is possible to modu-
late the intensity of this regimen without signiﬁcantly
Figure 3. Improvement in hematologic parameters after donor engraftment. The fraction of sickle Hb (S and D) is depicted in relation to serial
measurements of Hb concentration, reticulocyte count, and donor chimerism after transplantation. Patients 2 and 6 had Hb SS and donors
with Hb AA. Patient 1 has the genotype Hb SDLA and a donor with Hb AS; thus, the percentage of Hb DLA is plotted. Because the fraction
of Hb D was equivalent to the fraction of Hb S in sickle erythrocytes before transplantation in this patient, the total fraction of abnormal Hb
in recipient cells should be twice what is plotted. A suppression of reticulocytosis was observed among patients who had mixed chimerism, even
when the Hb concentration was less than normal. MMF was restarted in patient 6 on day 161 when donor chimerism was noted to have
decreased. After several stable donor chimerism measurements, the dose of MMF was decreased on day 182 because of myelosuppression. It
was increased on day 224 when donor chimerism was again noted to have decreased, but donor engraftment was lost. d/c indicates discontinued.
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increasing its toxicity and establish stable donor en-
graftment in most recipients. By incrementally in-
creasing the intensity of transplant conditioning, it
may be possible to identify an immunosuppressive
regimen that is sufﬁcient for engraftment yet mini-
mizes the risk of toxicity. Strategies that might also
reduce the risk of GVHD include the use of T cell–
depleting antibodies and posttransplantation cyclo-
phosphamide, and these additions to the regimens
tested here might represent suitable modiﬁcations.
Finding the minimally toxic regimen for achieving the
goal of stable donor engraftment may transform the
application of allogeneic transplantation for SCD.
ACKNOWLEDGMENTS
Special thanks to Melinda Patience and Cathy
Freer for their work in collecting data on the patients
described in this article. This work was supported by
National Institutes of Heath grant nos. K23-CA83779
(A.R.C.); HL 68091 and RR 01271 (M.C.W.); and
CA78902, HL36444, and CA15704 (R.F.S.).
REFERENCES
1. Walters MC. Bone marrow transplantation for sickle cell dis-
ease: where do we go from here? J Pediatr Hematol Oncol.
1999;21:467-474.
2. Walters MC, Storb R, Patience M, et al. Impact of bone
marrow transplantation for symptomatic sickle cell disease: an
interim report. Blood. 2000;95:1918-1919.
3. Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson
FL. Bone marrow transplantation for sickle cell disease. A study
of parents’ decisions. N Engl J Med. 1991;325:1349-1353.
4. van Besien K, Koshy M, Anderson-Shaw L, et al. Allogeneic
stem cell transplantation for sickle cell disease. A study of
patients’ decisions. Bone Marrow Transplant. 2001;28:545-549.
5. Walters MC, Patience M, Leisenring W, et al. Barriers to bone
marrow transplantation for sickle cell anemia. Biol Blood Marrow
Transplant. 1996;2:100-104.
6. Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic
chimerism in DLA-identical littermate dogs given sublethal
total body irradiation before and pharmacological immunosup-
pression after marrow transplantation. Blood. 1997;89:3048-
3054.
7. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor cells with purine analog-containing
chemotherapy: harnessing graft-versus-leukemia without my-
eloablative therapy. Blood. 1997;89:4531-4536.
8. Khouri IF, Keating M, Korbling M, et al. Transplant-lite:
induction of graft-versus-malignancy using ﬂudarabine-based
nonablative chemotherapy and allogeneic blood progenitor-cell
transplantation as treatment for lymphoid malignancies. J Clin
Oncol. 1998;16:2817-2824.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to con-
ventional bone marrow transplantation with lethal cytoreduc-
tion for the treatment of malignant and nonmalignant hema-
tologic diseases. Blood. 1998;91:756-763.
10. Niederwieser D, Maris M, Shizuru J, et al. Low-dose total body
irradiation (TBI) and ﬂudarabine followed by hematopoietic
cell transplantation (HCT) from HLA-matched or mismatched
unrelated donors and postgrafting immunosuppression with
cyclosporine and mycophenolate mofetil (MMF) can induce
durable complete chimerism and sustained remissions in pa-
tients with hematological diseases. Blood. 2003;101:1620-1629.
11. Iannone R, Luznik L, Engstron LW, et al. Effects of mixed
hematopoietic chimerism in a mouse model of bone marrow
transplantation for sickle cell anemia. Blood. 2001;97:3960-
3965.
12. Kean LS, Durham MM, Adams AB, et al. A cure for murine
sickle cell disease through stable mixed chimerism and toler-
ance induction after nonmyeloablative conditioning and major
histocompatibility-mismatched bone marrow transplant. Blood.
2001;99:1840-1849.
13. Walters MC, Patience M, Leisenring W, et al. Stable mixed
hematopoietic chimerism after bone marrow transplantation
for sickle cell anemia. Biol Blood Marrow Transplant. 2001;12:
665-673.
14. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed
chimerism in patients transplanted for the treatment of thalas-
semia. Blood. 1996;87:3494-3499.
15. Hawkins AL, Jones RJ, Zehnbauer BA, et al. Fluorescence
in-situ hybridization to determine engraftment status after mu-
Figure 3 Continued.
Nonmyeloablative BMT for SCD
527BB&MT
rine bone marrow transplant. Cancer Genet Cytogenet. 1992;64:
145-148.
16. Shulman H, Wells D, Gooley T, Myerson D, Bryant E, Loken
M. The biological signiﬁcance of rare peripheral blasts after
hematopoietic stem cell transplant is predicted by multidimen-
sional ﬂow cytometry. Am J Clin Pathol. 1999;112:513-523.
17. Sandmaier BM, Maloney DG, Hegenbart U, et al. Nonmyeloa-
blative conditioning for HLA-identical related allografts for
hematologic malignancies [abstract]. Blood 2000;96:479a.
18. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow trans-
plantation without myeloablation for sickle cell disease. N Engl
J Med. 2001;344:68.
19. Schleuning M, Stoetzer O, Waterhouse C, Schlemmer M,
Ledderose G, Kolb HJ. Hematopoietic stem cell transplanta-
tion after reduced-intensity conditioning for sickle cell disease.
Exp Hematol. 2002;30:7-10.
20. van Besien K, Bartholomew A, Stock W, et al. Fludarabine-
based conditioning for allogeneic transplantation in adults
with sickle cell disease. Bone Marrow Transplant. 2000;26:
445-449.
R. Iannone et al.
528
